Gland Pharma Limited

Gland Pharma Limited

Gland Pharma Limited has received approval for Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL Single-Dose Vials from the United States Food and Drug Administration (FDA). The company has successfully launched the product on the market, with sales of over $11 billion for the month of April 2026. Gland Pharma was established in 1978 and has grown over the years to become one of the largest pharmaceutical companies in India, with a global presence in over 60 countries.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Copy of Newspaper Publication. The company has published a copy of the newspaper publication in the newspapers Business Standard and Business Standard on 22nd August 2022. The publication includes the company's annual general meeting notice, the company's address, and the contact details of the company's representatives.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Schedule of meet

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding Change in Director(s) of the company. Mr. Uday Jahangeer Vetter has been appointed as Independent Director for a period of five consecutive years with effect from July 11, 2022, and Mr. William Robert Keller has been appointed as Independent Director for a period of five consecutive years with effect from June 15, 2022.

Gland Pharma Limited

Gland Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot and informed the Exchange regarding voting results.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Action(s) taken or orders passed. The company has been issued with an order-in-original dated July 11, 2022, by the Principal Commissioner of Customs, Hyderabad, regarding the detention of goods worth Rs. 33,55,22,993,667,788. The company has been directed to pay the amount of Rs. 33,55,22,993,667,788 along with interest and penalty. The company has been given time to appeal against the order.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming that the securities received from the depository participants for dematerialization during the quarter ended June 30, 2022, have been accepted and listed on the stock exchanges where the equity shares are issued.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Gland Pharma Limited

Gland Pharma Limited has informed the exchanges about a scheduled one-on-one meeting with institutional investor Ambit PMSS, arranged by B&K / 360One. This meeting is slated for June 25, 2026, as a routine engagement with the investment community. The announcement is a procedural disclosure of an investor interaction, with no specific agenda or material information disclosed at this stage. Such meetings are a standard part of investor relations.

Gland Pharma Limited

Gland Pharma Limited has informed the stock exchanges about the submission of a copy of a newspaper publication. The provided announcement primarily contains administrative details, including addresses for BSE and NSE, and mentions a future date of June 19, 2026. However, the specific content or subject matter of the newspaper publication itself is not detailed within this communication. Consequently, investors cannot discern any key financial figures, decisions, or their implications from this update alone. This appears to be an administrative compliance notification rather than a disclosure of substantive news.

Gland Pharma Limited

Gland Pharma Limited has informed the Exchange regarding Notice of Postal Ballot for approval of certain business resolutions.